retatrutide mechanism of action triple agonist glp-1 gip glucagon Retatrutide, a agonist, delivered 30.3% weight loss at two years in Phase 3. The headlines state: → 70 lbs average loss on 12mg at 80 weeks (28.3% body weight) → The Road towards Triple Agonists:
Description
Products like Trulicity and Victoza have established themselves as essential therapies in endocrinology protocols, often replacing older medications like sulfonylureas
The study design incorporated two reference groups (diabetes and overweight/obese), to reduce the influence of potential confounding variables
doi: 10.1016/j.japh.2023.10.002
There have been significant advances in type 2 diabetes mellitus management within the past decade
Note that 75 grams of sugar is around cup of granulated sugar
